ALX OncologyALXO
About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees: 89
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
487% more call options, than puts
Call options by funds: $364K | Put options by funds: $62K
90% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 21
8.18% less ownership
Funds ownership: 94.49% [Q2] → 86.31% (-8.18%) [Q3]
16% less funds holding
Funds holding: 110 [Q2] → 92 (-18) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 36
72% less capital invested
Capital invested by funds: $297M [Q2] → $83.1M (-$214M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for ALXO.
Financial journalist opinion
Based on 3 articles about ALXO published over the past 30 days